Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352674 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL16414652 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL7651316 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL3458580 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL16415140 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL7914609 | 1.00 | NPC1 (0.50) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL704306 | 0.98 | NPC1 (0.47) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL489807 | 0.93 | TDP1 (0.44) | NPC1RAB9APAX8JAK2KCNH2 | |
| SCHEMBL709443 | 0.85 | TP53 (0.43) | NPC1RAB9APAX8JAK2TP53 | |
| SCHEMBL11825722 | 0.82 | NPC1 (0.46) | NPC1RAB9APAX8JAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7858610-B2 | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-5352719-A | Blended with synthetic or natural polymers | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1994-10-04 | — | — | US | disclosed |
| US-5338853-A | N-(2,2,6,6-tetraalkyl-4-piperidinyl)amic acid hydrazides; contain light stabilizing group and heat stabilizing group | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5318851-A | Curable composition with auxiliary curing agent; coatings | ELF ATOCHEM N.A., INC. (US) | 1994-06-07 | — | — | US | disclosed |
| US-5213897-A | Curable coating compositions containing an N-(2,2,6,6-tetraalkyl-4-piperidinyl)amic acid hydrazide | ELF ATOCHEM NORTH AMERICA, INC. | 1993-05-25 | — | — | US | disclosed |
| EP-0507333-A2 | Epoxy resins containing bound light stabilizing groups | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1992-10-07 | — | — | EP | disclosed |
| US-5132387-A | Polyme bound | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0494639-A2 | Hindered amine light stabilizer hydrazides for stabilizing polyurethane, polyurea and polyurethane-polyurea polymers | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1992-07-15 | — | — | EP | disclosed |
| US-5116976-A | HINDERED AMINE LIGHT STABILIZER HYDRAZIDES | ATOCHEM NORTH AMERICA, INC (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0467344-A1 | Hindered amine light stabilizer hydrazides | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0434080-A1 | Derivatives of N-hals-substituted amic acid hydrazides | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | NPC1 226/4885RAB9A 3477/4885PAX8 1591/4885 |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | NPC1 2859/4885RAB9A 515/4885PAX8 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.